Nuclear Transcriptional Condensates as Drivers and Therapeutic Targets in NPM1-mutated AML - PubMed
3 hours ago
- #AML
- #transcriptional condensates
- #NPM1 mutation
- NPM1-mutated AML is driven by aberrant HOX/MEIS1 expression.
- Mutant NPM1 forms nuclear condensates that concentrate transcriptional regulators on chromatin.
- Targeted disruption of these condensates may offer a precision therapeutic approach.
- Menin-KMT2A inhibitors, now FDA approved, show activity in this AML subtype.